Rewind Therapeutics develops novel re-myelinating therapies for patients suffering from Multiple Sclerosis (MS) and other myelin-related diseases. While marketed MS therapies are effective in fighting the symptoms, they are not capable of reversing or halting the myelin damage. New therapies able to repair such damage would mean a substantial breakthrough for patients with myelin disorder diseases.
Location: Belgium, Flemish Brabant, Heverlee
Total raised: $3.37M
Investors 1
| Date | Name | Website |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.08.2019 | Grant | $3.37M | - |